Methylseleninic acid downregulates hypoxia-inducible factor-1α in invasive prostate cancer

International Journal of Cancer

Volumn 130, Issue 6, 2012, Pages 1430-1439

  Sinha, Indu ^a   Null, Kevin ^a   Wolter, William ^b   Suckow, Mark A ^b   King, Tonya ^a   Pinto, John T ^c   Sinha, Raghu ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

HIF 1 ; hormone refractory prostate cancer; methylseleninic acid

Indexed keywords

ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METHYLSELENINIC ACID; OXYGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; LUNG METASTASIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT;

ANIMALS; ANOXIA; APOPTOSIS; CELL LINE, TUMOR; DOWN-REGULATION; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG; LUNG NEOPLASMS; MALE; NEOPLASM METASTASIS; ORGANOSELENIUM COMPOUNDS; PROCOLLAGEN-PROLINE DIOXYGENASE; PROSTATIC NEOPLASMS; RATS; RATS, WISTAR; SELENIUM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84856118899     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26141     Document Type: Article

References (48)

1. Quero L, Mongiat-Artus P, Ravery V, Maylin C, Desgrandchamps F, Hennequin C,. Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: a single institution experience. BMC Cancer 2008; 8: 26.
2. Antonarakis ES, Blackford AL, Garrett-Mayer E, Eisenberger MA,. Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review. J Clin Oncol 2007; 25: 4998-5008. (Pubitemid 350220434)
3. Thomlinson RH, Gray LH,. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955; 9: 539-49.
4. Brown JM, Giaccia AJ,. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408-16. (Pubitemid 28193601)
5. Marignol L, Coffey M, Lawler M, Hollywood D,. Hypoxia in prostate cancer: a powerful shield against tumour destruction? Cancer Treat Rev 2008; 34: 313-27.
6. Zhong H, Agani F, Baccala AA, Laughner E, Rioseco-Camacho N, Isaacs WB, Simons JW, Semenza GL,. Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res 1998; 58: 5280-4. (Pubitemid 28551099)
7. Semenza GL,. Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med 2002; 41: 79-83. (Pubitemid 34223708)
8. Salceda S, Caro J,. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997; 272: 22642-7. (Pubitemid 27386079)
9. 2 sensing. Science 2001; 292: 464-8. (Pubitemid 32335941)
10. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999; 15: 551-78. (Pubitemid 32250386)
11. Harris AL,. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47. (Pubitemid 37328806)
12. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL,. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 1999; 59: 3915-18. (Pubitemid 29393552)
13. Thomas SL, Zhong D, Zhou W, Malik S, Liotta D, Snyder JP, Hamel E, Giannakakou P,. EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle 2008; 7: 2409-17.
14. Park JY, Park JW, Suh SI, Baek WK,. D-glucosamine down-regulates HIF-1alpha through inhibition of protein translation in DU145 prostate cancer cells. Biochem Biophys Res Commun 2009; 382: 96-101.
15. Mirzoeva S, Kim ND, Chiu K, Franzen CA, Bergan RC, Pelling JC,. Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. Mol Carcinog 2008; 47: 686-700.
16. Lee DH, Lee YJ,. Quercetin suppresses hypoxia-induced accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha) through inhibiting protein synthesis. J Cell Biochem 2008; 105: 546-53.
17. Zhong H, Willard M, Simons J,. NS398 reduces hypoxia-inducible factor (HIF)-1alpha and HIF-1 activity: multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms. Int J Cancer 2004; 112: 585-95. (Pubitemid 39425938)
18. Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL,. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA 2009; 106: 2353-8.
19. Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J,. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 2006; 26: 2019-28. (Pubitemid 43346906)
20. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL,. Modulation of hypoxia inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60: 1541-5. (Pubitemid 30183422)
21. Semenza GL,. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29: 625-34.
22. Webber MM, Perez-Ripoll EA, James GT,. Inhibitory effects of selenium on the growth of DU-145 human prostate carcinoma cells in vitro. Biochem Biophys Res Commun 1985; 130: 603-9. (Pubitemid 16239385)
23. Pinto JT, Sinha R, Papp K, Facompre ND, Desai D, El-Bayoumy K,. Differential effects of naturally occurring and synthetic organoselenium compounds on biomarkers in androgen responsive and androgen independent human prostate carcinoma cells. Int J Cancer 2007; 120: 1410-17. (Pubitemid 46355374)
24. Jiang C, Wang Z, Ganther H, Lu J,. Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 2001; 61: 3062-70. (Pubitemid 32691955)
25. Willett WC, Polk BF, Morris JS, Stampfer MJ, Pressel S, Rosner B, Taylor JO, Schneider K, Hames CG,. Prediagnostic serum selenium and risk of cancer. Lancet 1983; 2: 130-4. (Pubitemid 13067428)
26. Greenwald P, Lieberman R,. Chemoprevention trials for prostate cancer. In:, Chung LWK, Isaacs WB, Simons JW, eds. Prostate cancer: biology, genetics, and the new therapeutics. New Jersey: Humana Press Inc., 2000. 499-518.
27. Brooks JD, Metter EJ, Chan DW, Sokoll LJ, Landis P, Nelson WG, Muller D, Andres R, Carter HB,. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 2001; 166: 2034-8. (Pubitemid 33065210)
28. Sinha R, Pinto JT, Facompre N, Kilheffer J, Baatz JE, El-Bayoumy K,. Effects of naturally occurring and synthetic organoselenium compounds on protein profiling in androgen responsive and androgen independent human prostate cancer cells. Nutr Cancer 2008; 60: 267-75. (Pubitemid 351451281)
29. Sinha R, El-Bayoumy K,. Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds. Curr Cancer Drug Targets 2004; 4: 13-28. (Pubitemid 38332561)
30. Pinto JT, Lee JI, Sinha R, Macewan ME, Cooper AJ,. Chemopreventive mechanisms of alpha-keto acid metabolites of naturally occurring organoselenium compounds. Amino Acids. 2010 Apr 10. [Epub ahead of print]. DOI: 10.1007/s00726-010-0578-3.
31. Hu H, Jiang C, Li G, Lu J,. PKB/AKT and ERK regulation of caspase-mediated apoptosis by methylseleninic acid in LNCaP prostate cancer cells. Carcinogenesis 2005; 26: 1374-81. (Pubitemid 41417880)
32. Wang L, Bonorden MJ, Li GX, Lee HJ, Hu H, Zhang Y, Liao JD, Cleary MP, Lu J,. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev Res (Phila) 2009; 2: 484-95.
33. Pollard M, Suckow MA,. Hormone-refractory prostate cancer in the Lobund-Wistar rat. Exp Biol Med 2005; 230: 520-6. (Pubitemid 41233150)
34. Rudolfsson SH, Bergh A,. Testosterone-stimulated growth of the rat prostate may be driven by tissue hypoxia and hypoxia-inducible factor-1alpha. J Endocrinol 2008; 196: 11-19. (Pubitemid 351234567)
35. Sinha R, Medina D,. Inhibition of cdk2 kinase activity by methylselenocysteine in synchronized mouse mammary epithelial cells. Carcinogenesis 1997; 18: 1541-7. (Pubitemid 28134777)
36. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A,. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996; 271: 32529-37.
37. Xia M, Huang R, Sun Y, Semenza GL, Aldred SF, Witt KL, Inglese J, Tice RR, Austin CP,. Identification of chemical compounds that induce HIF-1alpha activity. Toxicol Sci 2009; 112: 153-63.
38. Ip C, Thompson HJ, Zhu Z, Ganther HE,. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated Se metabolite is critical for cancer chemoprevention. Cancer Res 2000; 60: 2882-6. (Pubitemid 30395810)
39. Gonzalez-Moreno O, Segura V, Serrano D, Nguewa P, de las Rivas J, Calvo A,. Methylseleninic acid enhances the effect of etoposide to inhibit prostate cancer growth in vivo. Int J Cancer 2007; 121: 1197-1204. (Pubitemid 47293785)
40. Stewart GD, Ross JA, McLaren DB, Parker CC, Habib FK, Riddick AC,. The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int 2010; 105: 8-13.
41. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW,. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5.
42. Maynard MA, Ohh M,. The role of hypoxia-inducible factors in cancer. Cell Mol Life Sci 2007; 64: 2170-80. (Pubitemid 350103108)
43. Rankin EB, Giaccia AJ,. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008; 15: 678-85. (Pubitemid 351405072)
44. Unni E, Koul D, Yung WK, Sinha R,. Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro. Breast Cancer Res 2005; 7: R699-R707.
45. Dery MA, Michaud MD, Richard DE,. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 2005; 37: 535-40. (Pubitemid 40022930)
46. Jiang C, Ganther H, Lu J,. Monomethyl selenium-specific inhibition of MMP-2 and VEGF expression: implications for angiogenic switch regulation. Mol Carcinog 2000; 29: 236-50. (Pubitemid 32052668)
47. Kaczmarek M, Cachau RE, Topol IA, Kasprzak KS, Ghio A, Salnikow K,. Metal ions-stimulated iron oxidation in hydroxylases facilitates stabilization of HIF-1 alpha protein. Toxicol Sci 2009; 107: 394-403.
48. Chintala S, Toth K, Cao S, Durrani FA, Vaughan MM, Jensen RL, Rustum YM,. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha. Cancer Chemother Pharmacol 2010; 66: 899-911.